Ashish Varma

Ashish Varma from UBS inquired about United Therapeutics' confidence in the upcoming TETON-1 data for IPF, comparing it to the TETON-2 study, and asked for the latest insights on the competitive impact of Yutrepia on Tyvaso DPI and nebulizer patient additions.

Answer

Dr. Leigh Peterson (EVP of Product Development and Xenotransplantation) expressed high optimism for TETON-1, citing robust TETON-2 results and similar patient populations. Michael Benkowitz (President and COO) stated that Tyvaso remains the market leader, with initial competitive curiosity waning and referrals returning to pre-competitor launch levels. He noted a Q4/January lag in patient starts due to seasonality and weather, expecting sequential revenue growth by Q2.

Ashish Varma asked about the company's confidence in the upcoming TETON-1 data for IPF, comparing it to the TETON-2 study, and inquired about the latest impact from competitor Yutrepia on patient additions for DPI or nebulizer therapies.

Answer

Leigh Peterson, Executive Vice President of Product Development and Xenotransplantation, expressed high confidence in TETON-1, citing robust TETON-2 results and similar study populations. Michael Benkowitz, President and Chief Operating Officer, stated that Tyvaso remains the market leader, with competitor claims waning. He noted that referrals are at pre-competitor launch levels, though patient starts lagged due to Q4 seasonality and severe weather, but are now improving, with sequential revenue growth expected by Q2.